Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a strategic collaboration with Johnson & Johnson* to advance the discovery of novel in vivo CAR-T cell therapies.
The collaboration aims to develop next-generation in vivo CAR-T cell therapies with Kelonia’s proprietary iGPS® (in vivo Gene Placement System) platform for Johnson & Johnson’s targets of interest. In vivo CAR-T cell therapies represent a potentially transformative approach that aims to make these medicines more accessible and reduce the burden of treatment for patients.
“This collaboration reflects a growing momentum and is a powerful validation of Kelonia’s iGPS platform and its potential to define the future of in vivo CAR-T therapy,” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia. “By leveraging our in vivo gene delivery technology through this strategic partnership, we’re taking a major step on our journey toward democratizing CAR-T cell therapies.”
*Legal entity: Janssen Biotech, Inc.
About Kelonia Therapeutics
Kelonia is a clinical-stage company pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS®). The company’s elegant, cutting-edge in vivo gene delivery technology uses an advanced lentiviral vector particle harboring envelope modification to improve in vivo gene transfer efficiency and tropism molecules to facilitate tissue-specific delivery. Kelonia is building a pipeline of genetic medicines across a range of diseases, with the bold goal of making in vivo CAR-T cell therapies accessible to every patient in need, when and where they need them. Its lead candidate, KLN-1010, is an in vivo anti-BCMA CAR-T therapy for multiple myeloma being evaluated in a Phase 1 clinical trial. Learn more about Kelonia at https://www.keloniatx.com/ and follow us on LinkedIn and X.
Kelonia and iGPS are trademarks of Kelonia Therapeutics, Inc.